(0.26%) 5 168.00 points
(0.21%) 38 913 points
(0.25%) 18 045 points
(1.09%) $78.96
(0.56%) $2.15
(0.94%) $2 330.30
(2.74%) $27.42
(1.33%) $978.15
(-0.04%) $0.928
(-0.22%) $10.85
(-0.28%) $0.795
(0.02%) $91.47
25.00% € 20.60
Live Chart Being Loaded With Signals
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally...
Stats | |
---|---|
Объем за сегодня | 290 930 |
Средний объем | 0 |
Рыночная капитализация | 0.00 |
EPS | €0.230 ( 2022-06-29 ) |
Last Dividend | €0.163 ( 2022-08-18 ) |
Next Dividend | €0 ( N/A ) |
P/E | 17.31 |
ATR14 | €0 (0.00%) |
GSK plc Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
GSK plc Финансовые показатели
Annual | 2021 |
Выручка: | €34.11B |
Валовая прибыль: | €22.51B (65.99 %) |
EPS: | €1.102 |
FY | 2021 |
Выручка: | €34.11B |
Валовая прибыль: | €22.51B (65.99 %) |
EPS: | €1.102 |
FY | 2020 |
Выручка: | €34.10B |
Валовая прибыль: | €22.40B (65.68 %) |
EPS: | €1.426 |
FY | 2019 |
Выручка: | €33.75B |
Валовая прибыль: | €21.89B (64.85 %) |
EPS: | €1.158 |
Financial Reports:
No articles found.
GSK plc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.163 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.140 | 2004-02-18 |
Last Dividend | €0.163 | 2022-08-18 |
Next Dividend | €0 | N/A |
Payout Date | 2022-10-06 | |
Next Payout Date | N/A | |
# dividends | 75 | -- |
Total Paid Out | €12.75 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.13 | -- |
Div. Sustainability Score | 8.49 | |
Div.Growth Potential Score | 4.03 | |
Div. Directional Score | 6.26 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RLI.F | Ex Dividend Junior | 2023-08-17 | Annually | 0 | 0.00% | |
BFSA.DE | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
INS.DE | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
TII.DE | Ex Dividend Knight | 2023-07-28 | Quarterly | 0 | 0.00% | |
CPOF.F | Ex Dividend Junior | 2023-05-08 | Semi-Annually | 0 | 0.00% | |
M4I.DE | Ex Dividend Knight | 2023-10-05 | Quarterly | 0 | 0.00% | |
WAF.DE | Ex Dividend Junior | 2023-05-08 | Annually | 0 | 0.00% | |
EKT.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
OHB.DE | Ex Dividend Junior | 2023-05-26 | Annually | 0 | 0.00% | |
ACT.DE | Ex Dividend Junior | 2023-05-12 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.149 | 1.500 | 7.01 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0644 | 1.200 | 7.85 | 9.42 | [0 - 0.3] |
returnOnEquityTTM | 0.344 | 1.500 | 7.29 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.785 | -1.000 | 2.15 | -2.15 | [0 - 1] |
currentRatioTTM | 0.789 | 0.800 | -1.055 | -0.844 | [1 - 3] |
quickRatioTTM | 0.183 | 0.800 | -3.63 | -2.90 | [0.8 - 2.5] |
cashRatioTTM | 0.181 | 1.500 | -0.108 | -0.162 | [0.2 - 2] |
debtRatioTTM | 0.306 | -1.500 | 4.91 | -7.36 | [0 - 0.6] |
interestCoverageTTM | 7.03 | 1.000 | 8.51 | 8.51 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.998 | 2.00 | 9.33 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.261 | 2.00 | 9.37 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.606 | -1.500 | 3.58 | -5.37 | [0 - 2.5] |
grossProfitMarginTTM | 0.660 | 1.000 | 2.34 | 2.34 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.162 | 1.000 | 8.77 | 8.77 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.329 | 1.000 | 9.28 | 9.28 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.458 | -0.367 | [0.5 - 2] |
Total Score | 8.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.80 | 1.000 | 8.71 | 0 | [1 - 100] |
returnOnEquityTTM | 0.344 | 2.50 | 8.26 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.261 | 2.00 | 9.58 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.998 | 2.00 | 9.33 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.785 | 1.500 | 2.15 | -2.15 | [0 - 1] |
pegRatioTTM | -0.326 | 1.500 | -5.51 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.233 | 1.000 | 6.67 | 0 | [0.1 - 0.5] |
Total Score | 4.03 |
GSK plc
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа